中国血液净化

中国血液净化 ›› 2019, Vol. 18 ›› Issue (11): 766-768.doi: 10.3969/j.issn.1671-4091.2019.11.009

• 综述 • 上一篇    下一篇

骨硬化蛋白在肾性骨营养不良中的研究进展

董晶倩1,高山林2   

  1. 1河北医科大学研究生院
    2河北医科大学附属唐山工人医院肾内科

  • 收稿日期:2019-04-12 修回日期:2019-06-27 出版日期:2019-11-12 发布日期:2019-10-28
  • 通讯作者: 高山林tsgsl@sohu.com E-mail:tsgsl@sohu.com

Research progress in sclerostin in the pathogenesis of renal osteodystrophy

  1. 1Graduate School of Hebei Medical University, Shijiazhuang 050000, China;  2Department of Nephrology, Tangshan Workers Hospital Affiliated to Hebei Medical University, Tangshan 063000, China
  • Received:2019-04-12 Revised:2019-06-27 Online:2019-11-12 Published:2019-10-28

PDF

607

摘要： 【摘要】肾性骨营养不良是慢性肾脏病(chronic kindey disease，CKD)患者常见且严重的并发症之一，将增加患者骨折风险和病残率，严重影响其生存质量。骨硬化蛋白(sclerostin)是一种由骨细胞表达的糖蛋白，其能够对骨骼生长代谢的各个阶段产生影响，并且参与了肾性骨营养不良的发病过程，本综述将对骨硬化蛋白在肾性骨营养不良中的研究进展进行探讨。

关键词: 慢性肾脏病, 肾性骨营养不良, 骨硬化蛋白

Abstract: 【Abstract】Renal osteodystrophy is one of the common and serious complications in CKD patients, leading to a significant increase in fracture risk and morbidity and seriously affecting the quality of life. Sclerostin is a glycoprotein expressed by bone cells, affects bone growth and metabolism at all stages, and participates in the pathogenesis of renal osteodystrophy. This review introduces the advances in the study of sclerostin in renal osteodystrophy.

Key words: Chronic kidney disease, Renal osteodystrophy, Sclerostin

中图分类号: